1448297-52-6

Basic information

• Product Name: (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
• Synonyms: (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide;3-Methyl-L-valyl-(4R)-4-hydroxy-N-[4-(4-methyl-1,3-thiazol-5-yl)benzyl]-L-prolinamide;(2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrro;MDK-7526;(4R)-3-Methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide HCl
• CAS NO: 1448297-52-6
• Molecular Formula: C₂₂H₃₀N₄O₃S
• Molecular Weight: 467.03
• Mol File: 1448297-52-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 691.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.254±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.10±0.40(Predicted)
• CAS DataBase Reference: (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide(1448297-52-6)
• EPA Substance Registry System: (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide(1448297-52-6)

Safety Data

• Hazardous Substances Data: 1448297-52-6(Hazardous Substances Data)

Usage

Description

(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide is a complex organic compound with a five-membered ring structure, known as pyrrolidine, which is composed of four carbon atoms and one nitrogen atom. (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide features a chiral center, indicated by the prefix "(2S,4R)", suggesting that it is non-superimposable on its mirror image. It also contains a thiazolyl group, a heterocyclic compound with nitrogen and sulfur atoms, and benzyl groups derived from benzene. The presence of a carboxamide group, which is a functional group derived from carboxylic acids and amides, further characterizes this molecule. The exact properties, uses, and nature of this highly complex compound would require detailed chemical research for a comprehensive understanding.

Uses

Since the provided materials do not specify the uses of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, it is not possible to list its applications based on the given information. However, given the complexity of the compound and its structural features, it may have potential applications in various fields such as pharmaceuticals, materials science, or as a chemical intermediate in the synthesis of other compounds. Further research and experimentation would be necessary to determine its specific uses and benefits.

Upstream product

• 630421-46-4 (2S,4R)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxylic acid 
• 1448191-54-5 tert‐butyl (2S,4R)‐4‐hydroxy‐2‐({[4‐(4‐methyl‐1,3‐thiazol‐5‐yl)phenyl]methyl}carbamoyl)pyrrolidine‐1‐carboxylate 
• 1448189-30-7 1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methaneamine 
• 122957-57-7 4-(4-methyl-1,3-thiazol-5-yl)benzonitrile 
• 1448189-45-4 (2S,4R)-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide 
• 623-00-7 4-bromobenzenecarbonitrile 
• 1448189-90-9 (2S,4R)-4-hydroxy-N-{ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrochloride 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 3959-07-7 4-Bromobenzylamine 
• 1448189-98-7 tert‐butyl N‐[(2S)‐1‐[(2S,4R)‐4‐hydroxy‐2‐({[4‐(4‐methyl‐1,3‐thiazol‐5‐yl)phenyl]methyl}carbamoyl)pyrrolidin‐1‐yl]‐3,3‐dimethyl‐1‐oxobutan‐2‐yl]carbamate 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 630421-45-3 methyl (2S_.4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3.3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxylate 

Downstream Products

• 1448188-62-2 (2S',4R)-1-((1S)-2-acetamido-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 

Relevant articles and documents

MICROMOLECULAR COMPOUND SPECIFICALLYDEGRADING TAU PROTEIN, AND APPLICATION THEREOF

The present disclosure discloses a micromolecular compound specifically degrading tau protein, and an application thereof. The chemical structure of the micromolecular compound specifically degrading tau protein is TBM-L-ULM or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph or N-oxide thereof, TBM being a tau protein-binding moiety, L being a linking group, and ULM being a ubiquitin ligase-binding moiety, the tau protein-binding moiety and the ubiquitin ligase-binding moiety being connected by means of the linking group. The micromolecular compound specifically degrading tau protein may increase tau protein degradation in a cell, thereby decreasing tau protein content.

ANDROGEN RECEPTOR PROTEIN DEGRADERS

The present disclosure provides compounds represented by Formula (I): A—L—B (I), and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer.

Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization

Our recent investigation is focused on the discovery of anti-angiogenesis agents. Vascular normalization induced by anti-angiogenic agent appears to be a promising strategy. We have developed novel angiogenesis inhibitors with potency of promoting vascular normalization. Herein, we reported the design, synthesis and preliminary evaluation of proteolysis-targeting chimera (PROTACs) based on the previously developed anti-angiogenesis agents. Two PROTACs exhibited potent VEGFR-2 inhibition and anti-proliferative activity against HUVECs. Moreover, they were capable of reducing protein levels of VEGFR-2 in EA.hy926 cells without significant cytotoxicity against HEK293 cells. The novel PROTACs could be used to normalize the abnormal vessels, resulting in efficient delivery of drugs.